|
|
| |
|
La Fondazione ICONA |
|
|
|
Benvenuto |
|
|
 |
 Presentazione |
 |
|
|
 Presentation Folder |
|
|
|
Referenti Fondazione |
|
|
|
• Scientific Structure |
|
|
|
• Segreteria organizzativa |
|
|
• CRO |
|
|
|
Documenti |
 |
|
|
Pubblicazioni |
|
|
|
Presentazioni |
|
|
|
Newsletter |
|
|
|
Eventi Fondazione |
|
|
|
Centri |
|
|
|
Risorse web |
|
|
|
Abstract ICONA |
|
|
|
Congressi |
|
|
|
Amici di ICONA |
|
|
|
| |
|
|
| |
| |
Abstract ICONA ai Congressi Internazionali |
|
|
| |
Gli abstract presentati al CROI 2012
Seattle, 5 - 8 marzo 2012 |
|
| • |
Alteri C, Di Maio VC, Artese A, Costa G, Alcaro S, Andreoni M, Antinori A, Ceccherini-Silberstein F, Perno CF, and Svicher V
Specific RT Polymorphisms Tightly Modulate Virological Response to First Line FTC+TDF containing HAART and Affect the RT Interaction with FTC and/or TDF. |
|
| • |
Lapadula G, Cozzi-Lepri A, Gori A, Antinori A, Marchetti G, Chiodera A, Narciso P, Parruti G, Galli M, and d’Arminio Monforte A
Risk of AIDS and non AIDS-related events among patients with conserved CD4+ T-cell counts at baseline but blunted immune-response despite virological suppression after antiretroviral treatment |
|
| • |
Sabbatini F, Cozzi-Lepri A, Bandera A, Madeddu G,Bonora S, Tozzi V, Mastroianni C, Bonfanti P, Gori A, and d'Arminio Monforte A
Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of Italian HIV-Infected People |
|
|
 |
| |
|
|
|
|
|
| |
|
|
| |
Gli abstract presentati al CROI 2011
Boston, 27 febbraio - 2 marzo 2011 |
|
| • |
Relative prognostic value of serum-free light chains (sFLC) and effective HAART in predicting HIV-associated lymphoma and mortality (abs 863)
M. P. Trotta, P Lorenzini, M Bibas, M Galli, G Rizzardini, P Narciso, V Tozzi, L Pucillo, A d’Arminio Monforte, A Antinori, and ICONA Fundation Study Group |
|
| • |
Impaired CD4+ count response to cART in antiretroviral naive HIV-infected patients presenting with tubercolosis as AIDS-defining condition (abs 885)
A. Cingolani, A Cozzi-Lepri, A Castagna, D Goletti, A De Luca, P Scarpellini, I Fanti, A Antinori, A d’Arminio Monforte, E Girardi, and ICONA Fundation, ICC, UCSC, HSR Cohort Studies |
|
| • |
Role of immune activation and microbial traslocation in liver disease progression in HIV/HCV co-infected ARV-naïve patients with high CD4+ count (abs 936)
G Marchetti, A Cozzi-Lepri, G. M. Bellistrì, E Merlini, F Ceccherini-Silberstein, A De Luca, A Antinori, A Castagna, M Puoti, A d’Arminio Monforte for the Icona Fundation Study Group
|
|
|
 |
| |
|
|
|
|
|
| |
|
|
| |
Gli abstract presentati al Congresso IAS 2009
Città del Capo, 19-22 luglio 2009 |
|
| • |
Framingham risk score (FRS) in HIV-positive patients living in Italy: the Icona Foundation Study
A. d’Arminio Monforte, A. Cozzi-Lepri, A Antinori, A De Luca, C. Mussini, S.Lo Caputo, G. Cassola, G.Pellizzer, J. Vecchiet, P.Caramello, M. Montroni, A. Castagna
|
|
| • |
Abacavir treatment and biomarkers associated with cardiovascular disease (CVD) in HIV-1-infected patients on effective antiretroviral therapy
A De Luca, K. De Gaetano Donati, A. Cozzi-Lepri, A. De Curtis, M.R. Capobianchi, A. Antinori, G. Scalise, G. Magnani, V. Vullo, R. Cauda, L. Iacoviello, A. d'Arminio Monforte, ICONA Foundation Study Group |
|
| • |
Is there any potential for first line Etravirine use? Analysis from a large dataset of ART-naïve HIV infected patients undergoing resistance test.
M. Zaccarelli, A. Antinori, A. Cozzi-Lepri, G. Palamara, C. Mussini, M.M. Santoro, V. Spagnuolo, A. d'Arminio Monforte, C.F. Perno, F. Ceccherini-Silberstein, I.Co.Na Study Group |
|
|
 |
| |
|
|
|
|
|
| |
|
|
| |
Gli abstract presentati al
7th European HIV Drug Resistance Workshop
Stoccolma, 25-27 marzo 2009 |
|
| • |
Novel Patterns of Mutations in HBV Reverse Transcriptase Associated with Lamivudine Resistance in HBV+HIV Co-infected Patients
V Svicher, C Alteri, V Cento, C Gori, R Salpini, F Marcuccilli, A Bertoli, M Arlotti, M Puoti, N Ladisa, G Rizzardini, F Ceccherini-Silberstein, A D’Arminio Monforte, CF Perno, and the ICoNA study group. |
|
|
 |
| |
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
